Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

Report Code: PHM118B

Publish Date: Oct 2023

Publisher: BCC Publishing

Category: Pharmaceuticals

Download Report Overview

30% Off

Limited Period Offer

CUSTOMIZE NOW

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global progressive ataxia and weakness disorders market reached $32.0 billion in 2022, should reach $35.1 billion by 2023 and $57.2 billion by 2028 with a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2023-2028.

Report Includes

  • 34 data tables and 34 additional tables
  • An overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
  • Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
  • In-depth information (facts and figures) pertaining to the major factors influencing the market, including growth trends, upcoming technologies and future prospects
  • An estimate of the actual market size, a revenue forecast for the market, and a market share analysis based on product, technology, disease type, application, distribution channel and region
  • A discussion of the applications for treatment and therapy technologies
  • Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market
  • A review of patent activity pertaining to applications for neurodegenerative disorders in the pharmaceutical and biotechnology markets
  • Coverage of recent mergers and acquisitions (M&A) activity, venture fundings and other developments affecting the global market
  • An analysis of the competitive landscape based on recent developments, segmental revenues and operational integration of the leading companies
  • Profiles of the major players in the industry

Report Scope

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.

This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $32.0 billion
Market size forecast $57.2 billion
Growth rate CAGR of 10.2% for the forecast period of 2023-2028
Units considered $ Millions
Segments covered Technology, Disease Type, Disease, Distributive Channel,
Regions covered North America, Europe, Asia-Pacific, Rest of the World (RoW)
Key Market Drivers
  • Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
  • Technological Advancements and Product Launch
  • Increasing Expenditures for Health Care
  • Rise in Alcohol and Drug Use
Companies studied
ABBOTTACORDA THERAPEUTICS
AMERICAN REGENT INC.APOTEX INC.
APOTHECA INC.ASTELLAS PHARMA INC.
ASTRAZENECABAXTER
BRISTOL-MYERS SQUIBB CO.EISAI CO. LTD.
LILLYGILEAD SCIENCES INC.
GSK PLC.GLENMARK LIFE SCIENCES
JOHNSON & JOHNSON SERVICES INC.MERCK KGAA
NOVARTIS AGPFIZER INC.
F. HOFFMANN-LA ROCHE LTD.SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.TEVA PHARMACEUTICAL INDUSTRIES LTD.
Need pricing for multiple titles, a complete report bundle, or something specially curated to fit your budget? EXPLORE OFFERS

Frequently Asked Questions (FAQs)

The progressive ataxia and weakness disorders drug market is projected to grow from $32.0 billion in 2022 to $57.2 billion in 2028, at a compound annual growth rate (CAGR) of 10.2 % during the forecast period.
The key factors driving the growth of treatments for syndromes of progressive ataxia and weakness disorders- Global Market include:
  • Increasing Prevalence of Neurological Disorders including Progressive Ataxia and Weakness Disorders and Awareness
  • Technological advancements and product launch
  • Increasing Expenditures for Health Care and investments for treatment for syndrome of Progressive Ataxia and Weakness Disorders
  • Rise in alcohol and drug usage
In this report, the market is segmented based on type, technology, diseases, region and distributive channel. Based on the type, the market is segmented into progressive ataxia and progressive weakness disorders. Based on the technology, the market is segmented as small molecule, monoclonal antibody and others. Based on diseases, progressive ataxia is segmented as Friedreich ataxia, Machado Joseph disease/SCA3 and Gertsmann Straussler Scheinker diseases and progressive weakness disorders as multiple sclerosis, hereditary neuropathies, amyotrophic lateral sclerosis, progressive bulbar palsy and hereditary spastic paraplegia. Based on distributive channel, the market is segmented into retail pharmacy, hospital pharmacy and online pharmacy.
Progressive weakness disorders will dominate the market by the end of 2028.
The major players in the market are Novartis AG, Pfizer Inc., Sanofi, Roche Holding Ltd. And Teva Pharmaceuticals.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders180Free
Chapter- 1: Introduction8Free
Chapter- 2: Summary and Highlights5Free
Chapter- 3: Market Overview7Free
Chapter- 4: Market Dynamics8Free
Chapter- 5: Market Breakdown by Type and Technology14Free
Chapter- 6: Market Breakdown by Disease22Free
Chapter- 7: Market Breakdown by Region21Free
Chapter- 8: Market Breakdown by Distribution Channel6Free
Chapter- 9: Emerging Technologies and Developments5Free
Chapter- 10: ESG Development11Free
Chapter- 11: Patent Analysis6Free
Chapter- 12: M&A and Venture Funding Outlook and Competitive Landscape7Free
Chapter- 13: Company Profiles56Free
Chapter- 14: Appendix: Abbreviations4Free

Related Reports

Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

Published - May 2023 | Publisher - BCC Publishing | Code - BIO074D

The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.

Global Markets for Bioengineered Protein Drugs

Published - Apr 2023 | Publisher - BCC Publishing | Code - BIO009H

The global market for bioengineered protein drugs is estimated to increase from $354.1 billion in 2022 to reach $521.3 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.

Immunotherapy Drugs: Global Markets

Published - Apr 2021 | Publisher - BCC Publishing | Code - PHM249A

The global market for immunotherapy drugs should grow from $139.8 billion in 2020 to $204.4 billion by 2025, at compound annual growth rate (CAGR) of 7.9% for the period of 2020-2025.

Global Markets for Enzyme Inhibitors

Published - Jan 2018 | Publisher - Shalini Shahani Dewan | Code - BIO057C

The global market for enzyme inhibitors should reach $179.9 billion by 2022 from $168 billion in 2017 at a compound annual growth rate (CAGR) of 1.4%, from 2017 to 2022.

Track the Latest Global Tariff Developments

In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.

Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.

Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.

With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.

Ready to see what tariff means for your business?

Consult with our experts or request your custom Tariff Impact Brife today

Stay Informed, Stay Competitive

In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.

Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.

Our analysis includes:

  • Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
  • Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
  • Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.

With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.

Don't let tariffs catch you off guard—let our insights guide your strategy.

This is an Excel-only version of the report.

Report Includes

    Total Number of Tables in this Report: 68

  • Summary Table: Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorder Drugs, Through 2028
  • Summary Table: Global Market for Progressive Ataxia and Weakness Disorders, Through 2028
  • Table 1: Classification, by Primary Dysfunction
  • Table 2: Drugs Approved in Europe for Multiple Sclerosis, 2011-2022
  • Table 3: Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, Through 2028
  • Table 4: Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, Through 2028
  • Table 5: Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
  • Table 6: Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
  • Table 7: Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
  • Table 8: Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, Through 2028
  • Table 9: Global Market for Friedreich’s Ataxia Drugs, by Region, Through 2028
Sample Report

Recent Reports

Over-the-Counter (OTC) Drugs, and Vitamins & Dietary Supplements: Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - PHM050D

The global market for over-the- counter (OTC) drugs, vitamins and dietary supplements is expected to grow from $276.9 billion in 2025 and is projected to reach $371.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 6.1% during the forecast period of 2025 to 2030.

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

Published - May 2025 | Publisher - BCC Publishing | Code - PHM263B

This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.

The Global Influenza Market

Published - May 2025 | Publisher - BCC Publishing | Code - PHM049F

The global influenza market is expected to grow from $9.0 billion in 2024 and is projected to reach $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029. 

Liver Disease Treatments: The Global Market

Published - Apr 2025 | Publisher - BCC Publishing | Code - PHM057D

The global market for liver disease treatments is estimated to increase from $46.0 billion in 2024 to reach $69.1 billion by 2030, at a compound annual growth rate (CAGR) of 7.1% from 2025 through 2030.

Cancer Immunotherapy: Technologies and Global Markets

Published - Apr 2025 | Publisher - BCC Publishing | Code - PHM129C

The global cancer immunotherapy market is expected to grow from $144.2 billion in 2024 and is projected to reach $247.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2024 to 2029.

Top Trending Reports

Next-Generation Advanced Batteries: Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - FCB062B

The global market for next-generation advanced batteries is estimated to grow from $1.5 billion in 2024 to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 28.5% from 2024 through 2029.

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

Published - May 2025 | Publisher - BCC Publishing | Code - PHM263B

This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.

Global Markets and Manufacturing Technologies for Protein Drugs

Published - Apr 2025 | Publisher - BCC Publishing | Code - BIO021G

The global protein drugs market is expected to grow from $441.7 billion in 2024 and is projected to reach $655.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.

Biologic Therapeutic Drugs: Technologies and Global Markets

Published - May 2025 | Publisher - BCC Publishing | Code - BIO079F

The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.

Global Markets for Emerging Medical Device Technologies

Published - Mar 2025 | Publisher - BCC Publishing | Code - HLC191C

The global market for emerging medical devices is estimated to increase from $136.6 billion in 2024 to reach $223.9 billion by 2029, at a compound annual growth rate (CAGR) of 10.4% from 2024 through 2029.

Published - Oct-2012| Analyst - Shalini Shahani Dewan| Code - PHM118A

Report Highlights

The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders
Sample Report